Antibody-drug conjugates (ADC) sector Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
02:15
Feb 10
Feb 10
Korea has competitive ADC component edge
ADC is the most advanced targeted anticancer modality, with global annual growth in the high teens to low twenties and especially fast Asia-Pacific growth. Korea is not competing head-on with global pharma on complete drugs but has competitive specialists in essential ADC components such as linkers and payloads, making the Korean ADC value chain attractive.
MED
About Antibody-drug conjugates (ADC) sector Investor Commentary
Across the available history and selected sources, Buzzberg tracks Antibody-drug conjugates (ADC) sector across 1 sources: 1 bullish vs 0 bearish calls from 1 authors. Historical directional balance: 100% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 1 total trade idea tracked. Latest voices: Noh Young-rae.